Immunoassays | Prototype

Erenna® Aβ-42 Immunoassay Prototype Assay (Cat# 03-0021-AA)

download PDF data sheet

Introduction

The Erenna® Aβ-42 Immunoassay Evaluation Reagent Kit uses a quantitative fluorescent sandwich immunoassay technique to measure Aβ-42 in plasma and serum samples. A capture antibody specific for Aβ-42 has been pre-coated onto paramagnetic microparticles (MP). The user pipettes MP, standards, and samples into uncoated microplate wells. During incubation, the Aβ-42 present in the sample binds to the capture antibody on the coated MP. Unbound molecules are washed away during the subsequent buffer exchange and wash steps. Fluor-labeled detection antibody is added to each well and incubated. This detection antibody recognizes and binds to Aβ-42 that has been captured onto the MP. During the following wash step the MPs are transferred to a clean plate. Elution buffer is then added and incubated. The elution buffer dissociates the bound protein sandwich from the MP surface, releasing the labeled antibodies. These antibodies are separated during transfer to a final microplate. The plate is loaded into the Erenna System where the labeled molecules are detected and counted. The number of fluor-labeled detection antibodies counted is directly proportional to the amount of Aβ-42 present in the sample when captured. The amount of Aβ-42 in unknown samples is interpolated from a standard curve.

Assay Performance

¹ See product insert for updated values
² LLoQ = 20% CV and ± 20% recovery
³ based upon median [Aβ-42] in a healthy reference

FIGURE 1. Normal [Aβ-42] in 10 EDTA plasma donors, with median and interquartile range. The Erenna® Aβ-42 Immunoassay Evaluation Reagent Kit reliably quantifies Aβ-42 in healthy subjects, who have a median [Aβ-42] of 4.4 pg/mL that is well above the detection limit of 0.2 pg/mL.

FIGURE 2. Erenna® Aβ-42 Immunoassay Evaluation Reagent Kit low-end standard curve signal (left) and curve fit (right).

Representative data shown for demonstration purposes only. Individual results may vary depending upon samples tested and protocol used.

Biology and Disease

Amyloid beta proteins (40 and 42 amino acids) are the main constituent of amyloid plaques in the brains of Alzheimer’s disease (AD) patients. In healthy and disease states Aβ-40 is the more common form of the two (10–20X higher than Aβ-42) in both cerebrospinal fluid (CSF) and plasma. In patients with AD, Aβ-42 primarily aggregates and deposits in the brain forming plaques. Thus the effective concentration of Aβ-42 monomer is decreased in the CSF of many AD patients. Recent studies suggest that a decrease in Aβ-42 concentrations (with a paralleled change in the ratio of Aβ-40/Aβ-42) can be monitored and may indicate AD progression.

* Source Info from www.uniprot.org.

Related Products